Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard vs high-dose tinzaparin prophylaxis or anticoagulation in hospitalized patients with COVID-19 pneumonia at high thrombotic risk
2020-004279-42Phase 3Active
- Sponsor
- Fundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta Sofía y del Hospital Universitario del Henares
- Start
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tinzaparin in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia (3 arms), sponsored by Fundación para la Investigación e Innovación Biomédica del Hospital Universitario Infanta Sofía y del Hospital Universitario del Henares. Primary endpoint: Composite efficacy endpoint at day 30. Started Oct 2022; status: active.
02
Drugs
tinzaparin
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on 2020-004279-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004279-42.